NASDAQ:RMTI
Rockwell Medical Stock News
$1.77
+0.0250 (+1.44%)
At Close: May 17, 2024
Rockwell Medical, Inc. (RMTI) CEO Russell Ellison on Q3 2021 Results - Earnings Call Transcript
09:05pm, Monday, 15'th Nov 2021
Rockwell Medical, Inc. (RMTI) CEO Russell Ellison on Q3 2021 Results - Earnings Call Transcript
Rockwell Medical, Inc. Provides Third Quarter 2021 Financial and Operational Update
09:00pm, Monday, 15'th Nov 2021 Rockwell Medical
- Third quarter net sales of $16.0 Million , up 6% sequential quarter-over-quarter and 5% year-over-year - - Company recently submitted Investigational New Drug application with FDA for its proposed clinical trial of FPC as a treatment for iron deficiency anemia in patients receiving home
Rockwell Medical (RMTI) Reports Q3 Loss, Misses Revenue Estimates
06:29pm, Monday, 15'th Nov 2021
Rockwell Medical (RMTI) delivered earnings and revenue surprises of -14.29% and -11.47%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
Recap: Rockwell Medical Q3 Earnings
04:48pm, Monday, 15'th Nov 2021
Rockwell Medical (NASDAQ:RMTI) reported its Q3 earnings results on Monday, November 15, 2021 at 04:00 PM. Here's what investors need to know about the announcement.
Rockwell Medical: Down But By No Means Out
12:48pm, Tuesday, 05'th Oct 2021
Management continues to invest behind its FPC drug platform.
Rockwell Medical, Inc. to Present at the H.C. Wainwright 23rd Annual Global Investment Conference
09:52am, Thursday, 09'th Sep 2021
WIXOM, Mich., Sept. 09, 2021 (GLOBE NEWSWIRE) -- Rockwell Medical, Inc. (Nasdaq: RMTI), a biopharmaceutical company dedicated to transforming the treatment of iron deficiency and anemia management and
Rockwell Medical, Inc. Announces Inducement Grant Under Nasdaq Listing Rule 5635(C)(4)
04:00pm, Thursday, 19'th Aug 2021
WIXOM, Mich., Aug. 19, 2021 (GLOBE NEWSWIRE) -- Rockwell Medical, Inc. (Nasdaq: RMTI) (“Rockwell Medical” or the “Company”), a biopharmaceutical company dedicated to transforming the treatment
Rockwell Medical, Inc. (RMTI) CEO Russell Ellison on Q2 2021 Results - Earnings Call Transcript
12:40am, Tuesday, 17'th Aug 2021
Rockwell Medical, Inc. (RMTI) CEO Russell Ellison on Q2 2021 Results - Earnings Call Transcript
Rockwell Medical (RMTI) Reports Q2 Loss, Misses Revenue Estimates
07:48pm, Monday, 16'th Aug 2021
Rockwell Medical (RMTI) delivered earnings and revenue surprises of -12.50% and -11.64%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Recap: Rockwell Medical Q2 Earnings
04:45pm, Monday, 16'th Aug 2021
Shares of Rockwell Medical (NASDAQ:RMTI) fell 12.6% in after-market trading after the company reported Q2 results. Quarterly Results Earnings per share increased 0.00% over the past year to ($0.09), w
Rockwell Medical, Inc. Provides Second Quarter 2021 Financial and Operational Update
04:09pm, Monday, 16'th Aug 2021
-Entered into exclusive license agreement with Drogsan Pharmaceuticals for the rights to commercialize Triferic® in Turkey-
Rockwell Medical (RMTI) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
04:10pm, Monday, 09'th Aug 2021
Rockwell Medical (RMTI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
WIXOM, Mich., June 28, 2021 (GLOBE NEWSWIRE) -- Rockwell Medical, Inc. (Nasdaq: RMTI), a biopharmaceutical company dedicated to transforming the treatment of iron deficiency and anemia management and
Rockwell Medical's (RMTI) CEO Russell Ellison on Q1 2021 Results - Earnings Call Transcript
06:30pm, Monday, 17'th May 2021
Rockwell Medical's (RMTI) CEO Russell Ellison on Q1 2021 Results - Earnings Call Transcript
